Average Co-Inventor Count = 5.32
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Acea Therapeutics, Inc. (10 from 10 patents)
2. Acea Biosciences, Inc. (6 from 49 patents)
3. Neurogenetic Pharmaceuticals, Inc. (4 from 5 patents)
4. Bristol-Myers Squibb Compnay (1 from 3,693 patents)
5. Roche Palo Alto LLC (1 from 322 patents)
6. Bristol-Myers Squibb Pharma Company (1 from 234 patents)
7. Vivasor, Inc. (1 from 10 patents)
8. Torreypines Therapeutics, Inc. (1 from 1 patent)
9. Hangzhou Acea Pharmaceutical Research Co., Ltd. (1 from 1 patent)
10. Zhejiang Acea Pharmaceuticals Co., Ltd. (1 from 1 patent)
25 patents:
1. 12358895 - Process for manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and formulations thereof
2. 11987554 - Protease inhibitors as antivirals
3. 11753373 - Protease inhibitors as antivirals
4. 11612602 - Heterocyclic compounds and uses as anticancer agents
5. 11498922 - Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
6. 11007197 - EGFR modulators and uses thereof
7. 10799504 - Heterocyclic compounds and uses as anticancer agents
8. 10596174 - Pyrrolopyrimidine compounds as inhibitors of protein kinases
9. 10562918 - Heterocyclic compounds and uses thereof
10. 10533011 - Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
11. 10449196 - EGFR modulators and uses thereof
12. 9920074 - Heterocyclic compounds and uses thereof
13. 9763949 - EGFR modulators and uses thereof
14. 9586965 - Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
15. 9464089 - Heterocyclic compounds and uses thereof